Products
Online Inquiry
Agerafenib
Cat. No.:
0225LY-0771
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Add to basket
Product Overview
Description:
Agerafenib is a chemical compound characterized as a highly potent inhibitor of BRAF.
Synonym:
1188910-76-0; 1-[3-(6,7-dimethoxyquinazolin-4-yl)oxyphenyl]-3-[5-(1,1,1-trifluoro-2-methylpropan-2-yl)-1,2-oxazol-3-yl]urea; 1-(3-((6,7-dimethoxyquinazolin-4-yl)oxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea; Urea, N-[3-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N-[5-(2,2,2-trifluoro-1,1-dimethylethyl)-3-isoxazolyl]-; 1-(3-(6,7-Dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea
CAS No.:
1188910-76-0
Compound CID:
56846693
Formula:
C24H22F3N5O5
Formula Weight:
517.46
Specification
Targets&IC50:
PDGFRβ: 2 nM(Kd); c-Kit: 2 nM(Kd); Abl-1: 3 nM(Kd); RET: 2 nM(Kd); Lck: 2 nM(Kd)
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Agerafenib can be used in kinase research to evaluate the selective inhibition of RAF kinases in various cancer models.
Library Information
Target:
Raf; c-Kit; PDGFR; Src; Bcr-Abl; c-RET
Receptor:
Abl1; c-Kit; Lck; PDGFRβ; Raf; RET
Pathways:
MAPK; Apoptosis; Cytoskeletal signaling; Angiogenesis; Tyrosine kinase/adaptors
Plate Number:
AOCL-10
Plate Location:
h9
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
45 mg/mL; 86.96 mM
Ethanol Max Solubility:
<1 mg/mL (insoluble or slightly soluble)
ALogP:
5.288
HBA_Count:
8
HBD_Count:
2
Rotatable Bond:
8
